The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Open accessAbstract
Comparison 1 AI versus non-AI, Outcome 1 Overall survival (reported or calculated). . . . . . .Analysis 1.2.Comparison 1 AI versus non-AI, Outcome 2 Progression-free survival (reported or calculated). . . .Analysis 1.3.Comparison 1 AI versus non-AI, Outcome 3 Clinical benefit (assessable). . . . . . . . . . . .Analysis 1.4.Comparison 1 AI versus non-AI, Outcome 4 Objective response (assessable). . . . . . . . . .Analysis 1.5.Comparison 1 AI versus non-AI, Outcome 5 Clinical benefit (randomised). . . . . . . . . . .Analysis 1.6.Comparison 1 AI versus non-AI, Outcome 6 Objective response (randomised). . . . . . . . . .Analysis 2.1.Comparison 2 AI versus non-AI: Toxicity, Outcome 1 hot flushes. . . . . . . . . . . . . .Analysis 2.2.Comparison 2 AI versus non-AI: Toxicity, Outcome 2 nausea. . . . . . . . . . . . . . . .Analysis 2.3.Comparison 2 AI versus non-AI: Toxicity, Outcome 3 vomiting. . . . . . . . . . . . . . .Analysis 2.4.Comparison 2 AI versus non-AI: Toxicity, Outcome 4 diarrhoea. . . . . . . . . . . . . . .Analysis 2.5.Comparison 2 AI versus non-AI: Toxicity, Outcome 5 rash. . . . . . . . . . . . . . . .Analysis 2.6.Comparison 2 AI versus non-AI: Toxicity, Outcome 6 vaginal bleeding. . . . . . . . . . . .Analysis 2.7.Comparison 2 AI versus non-AI: Toxicity, Outcome 7 thromboembolic. . . . . . . . . . . .Analysis 2.8.Comparison 2 AI versus non-AI: Toxicity, Outcome 8 arthralgia. . . . . . . . . . . . . . .Analysis 3.1.Comparison 3 Current AIs versus non-AI, Outcome 1 Overall survival (reported or calculated). . . .Analysis 3.2.Comparison 3 Current AIs versus non-AI, Outcome 2 Progression-free survival (reported or calculated).Analysis 3.3.Comparison 3 Current AIs versus non-AI, Outcome 3 Clinical benefit (assessable). . . . . . . .Analysis 3.4.Comparison 3 Current AIs versus non-AI, Outcome 4 Objective response (assessable). . . . . . .Analysis 3.5.Comparison 3 Current AIs versus non-AI, Outcome 5 Clinical benefit (randomised). . . . . . . .Analysis 3.6.Comparison 3 Current AIs versus non-AI, Outcome 6 Objective response (randomised). . . . . .Analysis 4.1.Comparison 4 Current AIs versus non-AI: Toxicity, Outcome 1 hot flushes. . . . . . . . . . .Analysis 4.2.Comparison 4 Current AIs versus non-AI: Toxicity, Outcome 2 nausea. . . . . . . . . . . .Analysis 4.3.Comparison 4 Current AIs versus non-AI: Toxicity, Outcome 3 vomiting. . . . . . . . . . .Analysis 4.4.Comparison 4 Current AIs versus non-AI: Toxicity, Outcome 4 diarrhoea. . . . . . . . . . .Analysis 4.5.Comparison 4 Current AIs versus non-AI: Toxicity, Outcome 5 rash. . . . . . . . . . . . .Analysis 4.6.Comparison 4 Current AIs versus non-AI: Toxicity, Outcome 6 vaginal bleeding. . . . . . . . .Analysis 4.7.Comparison 4 Current AIs versus non-AI: Toxicity, Outcome 7 thromboembolic. . . . . . . . .Analysis 4.8.Comparison 4 Current AIs versus non-AI: Toxicity, Outcome 8 arthralgia. . . . . . . . . . .Analysis 5.1.Comparison 5 AI versus different AI, Outcome 1 Overall survival (reported). . . . . . . . . .Analysis 5.2.Comparison 5 AI versus different AI, Outcome 2 Progession-free survival (reported or calculated). . .Analysis 5.3.Comparison 5 AI versus different AI, Outcome 3 Clinical benefit (assessable). . . . . . . . . .Analysis 5.4.Comparison 5 AI versus different AI, Outcome 4 Objective response (assessable). . . . . . . . .Analysis 5.5.Comparison 5 AI versus different AI, Outcome 5 Clinical benefit (randomised). . . . . . . . .Analysis 5.6.Comparison 5 AI versus different AI, Outcome 6 Objective response (randomised). . . . . . . .Analysis 6.1.Comparison 6 AI as first-line therapy versus any other therapy (tamoxifen), Outcome 1 Overall survival (reported or calculated). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Analysis 6.2.Comparison 6 AI as first-line therapy versus any other therapy (tamoxifen), Outcome 2 Progression-free survival (reported or calculated). . . . . . . . . . . . . . . . . . . . . . . . . . . .i Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women (Review)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Hao (2015) · doi:10.1002/14651858 · Cited by 11,321
Cancer incidence, mortality and prevalence worldwide
Ferlay, J. (2004) · Medical Entomology and Zoology · Cited by 3,796
Beatson, G. (1896) · The Lancet · doi:10.1016/s0140-6736(01)72384-7 · Cited by 1,608
Globocan 2000 : cancer incidence, mortality and prevalence worldwide
Ferlay, J., Pisani, P., & Parkin, D. M. (2001) · Medical Entomology and Zoology · Cited by 1,579
Beatson, G. (1896) · The Lancet · doi:10.1016/s0140-6736(01)72307-0 · Cited by 1,282
Mouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Jänicke, F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2596 · Cited by 1,015
Nabholtz, J. M., Buzdar, A., Pollak, M., Harwin, W., Burton, G., Mangalik, A., Steinberg, M., Webster, A., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3758 · Cited by 992
Bonneterre, J., Thürlimann, B., Robertson, J. F. R., Krzakowski, M., Mauriac, L., Koralewski, P., Vergote, I., Webster, A., Steinberg, M., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3748 · Cited by 842
Smith, I. E., Dowsett, M., Ebbs, S. R., Dixon, J. M., Skene, A., Blohmer, J.-U., Ashley, S. E., Francis, S., Boeddinghaus, I., & Walsh, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.005 · Cited by 774
Mouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Jaenicke, F., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.194 · Cited by 746
Survival Analysis: A Practical Approach.
Smith, P. J., Parmar, M. K. B., & David, M. (1996) · Journal of the American Statistical Association · doi:10.2307/2291609 · Cited by 730
Eiermann, W., Paepke, S., Appfelstaedt, J., Llombart-Cussac, A., Eremin, J., Vinholes, J., Mauriac, L., Ellis, M., Lassus, M., Chaudri-Ross, H. A., et al. (2001) · Annals of Oncology · doi:10.1023/a:1013128213451 · Cited by 713
Howell, A., Robertson, J. F. R., Quaresma Albano, J., Aschermannova, A., Mauriac, L., Kleeberg, U. R., Vergote, I., Erikstein, B., Webster, A., & Morris, C. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.057 · Cited by 671
Osborne, C. K., Pippen, J., Jones, S. E., Parker, L. M., Ellis, M., Come, S., Gertler, S. Z., May, J. T., Burton, G., Dimery, I., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.058 · Cited by 642
Dombernowsky, P., Smith, I., Falkson, G., Leonard, R., Panasci, L., Bellmunt, J., Bezwoda, W., Gardin, G., Gudgeon, A., Morgan, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.453 · Cited by 638
Hayward, J. L., Carbone, P. P., Heuson, J.-C., Kumaoka, S., Segaloff, A., & Rubens, R. D. (1977) · Cancer · doi:10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f · Cited by 623
Geisler, J., Haynes, B., Anker, G., Dowsett, M., & Lønning, P. E. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.751 · Cited by 604
Bonneterre, J., Buzdar, A., Nabholtz, J.-M. A., Robertson, J. F. R., Th�rlimann, B., von Euler, M., Sahmoud, T., Webster, A., Steinberg, M., & Arimidex Writing Committee on behalf of the Investigators Committee Members (2001) · Cancer · doi:10.1002/1097-0142(20011101)92:9<2247::aid-cncr1570>3.0.co;2-y · Cited by 574
Gordon, D. (1976) · The Lancet · doi:10.1016/s0140-6736(76)92329-1 · Cited by 552
Kaufmann, M., Bajetta, E., Dirix, L. Y., Fein, L. E., Jones, S. E., Zilembo, N., Dugardyn, J.-L., Nasurdi, C., Mennel, R. G., Cervek, J., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1399 · Cited by 521
Chia, S., Gradishar, W., Mauriac, L., Bines, J., Amant, F., Federico, M., Fein, L., Romieu, G., Buzdar, A., Robertson, J. F. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5822 · Cited by 513
Buzdar, A. U., Jonat, W., Howell, A., Jones, S. E., BLOMQVIST, C. P., Vogel, C. L., EIERMANN, W., Wolter, J. M., Steinberg, M., Webster, A., et al. (1998) · PubMed · Cited by 417
Buzdar, A., Jonat, W., Howell, A., Jones, S. E., Blomqvist, C., Vogel, C. L., Eiermann, W., Wolter, J. M., Azab, M., Webster, A., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2000 · Cited by 406
Buzdar, A., Douma, J., Davidson, N., Elledge, R., Morgan, M., Smith, R., Porter, L., Nabholtz, J., Xiang, X., & Brady, C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3357 · Cited by 365
Cataliotti, L., Buzdar, A. U., Noguchi, S., Bines, J., Takatsuka, Y., Petrakova, K., Dube, P., & Tosello de Oliveira, C. (2006) · Cancer · doi:10.1002/cncr.21872 · Cited by 352
Geisler, J., King, N., Dowsett, M., Ottestad, L., Lundgren, S., Walton, P., Kormeset, P., & Lønning, P. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.531 · Cited by 336
Robertson, J. F. R., Osborne, C. K., Howell, A., Jones, S. E., Mauriac, L., Ellis, M., Kleeberg, U. R., Come, S. E., Vergote, I., Gertler, S., et al. (2003) · Cancer · doi:10.1002/cncr.11468 · Cited by 315
Mauri, D., Pavlidis, N., Polyzos, N. P., & Ioannidis, J. P. A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj357 · Cited by 286
Gershanovich, M., Chaudri, H. A., Campos, D., Lurie, H., Bonaventura, A., Jeffrey, M., Buzzi, F., Bodrogi, I., Ludwig, H., Reichardt, P., et al. (1998) · Annals of Oncology · doi:10.1023/a:1008226721932 · Cited by 259
Jonat, W., Howell, A., Blomqvist, C., Eiermann, W., Winblad, G., Tyrrell, C., Mauriac, L., Roche, H., Lundgren, S., Hellmund, R., et al. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00014-3 · Cited by 254
Dowsett, M., Jones, A. L., Johnston, S. R. D., Jacobs, S., Trunet, P. F., & Smith, I. E. (1995) · PubMed · Cited by 238
Paridaens, R., Dirix, L., Lohrisch, C., Beex, L., Nooij, M., Cameron, D., Biganzoli, L., Cufer, T., Duchateau, L., Hamilton, A., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg362 · Cited by 230
An open randomised trial of second-line endocrine therapy in advanced breast cancer
Rose, C., Vtoraya, O., Pluzanska, A., Davidson, N., Gershanovich, M., Thomas, R., Johnson, S., Caicedo, J. J., Gervasio, H., Manikhas, G., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00630-0 · Cited by 192
Nabholtz, J. M., Bonneterre, J., Buzdar, A., Robertson, J. F. R., & Thürlimann, B. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00326-5 · Cited by 176
Arimidex Study Group, Buzdar, A. U., Jonat, W., Howell, A., Jones, S. E., Blomqvist, C. P., Vogel, C. L., Eiermann, W., Wolter, J. M., Steinberg, M., et al. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980915)83:6<1142::aid-cncr13>3.0.co;2-5 · Cited by 174
Dixon, J. M., Renshaw, L., Bellamy, C. O. C., Stuart, M., Hoctin-Boes, G., & Miller, W. R. (2000) · PubMed · Cited by 143
Milla-Santos, A., Milla, L., Portella, J., Rallo, L., Pons, M., Rodes, E., Casanovas, J., & Puig-Gali, M. (2003) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000047126.10522.f9 · Cited by 142
Dowsett, M., Cunningham, D., Stein, R. C., Evans, S., Dehennin, L., Hedley, A. J., & Coombes, R. C. (1989) · PubMed · Cited by 140
Serum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen
Lipton, A., Ali, S. M., Leitzel, K., Demers, L., Harvey, H. A., Chaudri‐Ross, H. A., Brady, C., Wyld, P. J., & Carney, W. P. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.098 · Cited by 124
Buzdar, A. U., Smith, R. A., Vogel, C. L., Bonomi, P., Keller, A. M., Favis, G., Mulagha, M. T., Cooper, J., & for the Multi-Institutional Trialist Collaborative Study Group (1996) · Cancer · Cited by 118
Goss, P. E., Winer, E. P., Tannock, I. F., & Grou, L. H. S. O. B. O. T. N. A. V. S. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.52 · Cited by 111
Carrion, R. P., Candel, V. A., Calabresi, F., Michel, R. T., dos Santos, R. B., Delozier, T., Goss, P. E., Mauriac, L., Feuilhade, F., & Freue, M. (1994) · PubMed · Cited by 99
Thurlimann, B. J. K., Beretta, K., Bacchi, M., Castiglione‐Gertsch, M., Goldhirsch, A., Jungi, W. F., Cavalli, F., Senn, H.-J., Fey, M. F., & Löhnert, T. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010635 · Cited by 95
Thurlimann, B. J. K., Robertson, J. F. R., Nabholtz, J., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00602-6 · Cited by 89
Atalay, G., Dirix, L. Y., Biganzoli, L., Beex, L. V. A. M., Nooij, M. A., Cameron, D., Lohrisch, C. A., Čufer, T., Lobelle, J. P., Mattiaci, M. R., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh064 · Cited by 88
Dowsett, M., Stein, R. C., Mehta, A., & Coombes, R. C. (1990) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1990.tb00906.x · Cited by 85
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Gibson, L., Dawson, C., Lawrence, D., & Bliss, J. M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003370.pub2 · Cited by 73
Self-citationBajetta, E., Zilembo, N., Dowsett, M., Guillevin, L., Leo, A. D., Celio, L., Martinetti, A., Marchianò, A. V., Pozzi, P., Stani, S. C., et al. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00392-x · Cited by 69
Mauriac, L., Pippen, J., Albano, J., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00199-0 · Cited by 69
Raats, J., Falkson, G., & Hc, F. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.111 · Cited by 67
Falkson, C. I., & Hc, F. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010634 · Cited by 66
Ingle, J. N., JOHNSON, P. A., Suman, V. J., Gerstner, J. B., Mailliard, J. A., Camoriano, J. K., Gesme, D. H., Loprinzi, C. L., Hatfield, A. K., & Hartmann, L. C. (1997) · Cancer · Cited by 63
Ingle, J. N., Green, S., Ahmann, D. L., Long, H. J., Edmonson, J. H., Rubin, J., Chang, M. N., & Creagan, E. T. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.6.958 · Cited by 58
Miller, W. R. (1996) · Endocrine Related Cancer · doi:10.1677/erc.0.0030065 · Cited by 53
Recent advances in endocrine therapy of breast cancer
Howell, A., & Dowsett, M. (1997) · BMJ · doi:10.1136/bmj.315.7112.863 · Cited by 51
The minimal effective exemestane dose for endocrine activity in advanced breast cancer
Bajetta, E., Zilembo, N., Noberasco, C., et al. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00494-7 · Cited by 46
Robertson, J. F. R., Howell, A., Buzdar, A. U., von Euler, M., & Lee, D. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006391902868 · Cited by 40
Alonso, M. C., Ojeda-González, M. B., Beltran-Fabregat, M., Ribugent, J. D., López-López, L., Borrás-Balada, J., Cardenal-Alemany, F., Gómez‐Batiste, X., Fabregat-Mayol, J., & Viladiu-Quemada, P. (2009) · Oncology · doi:10.1159/000226639 · Cited by 39
Tominaga, T., Adachi, I., Sasaki, Y., Tabei, T., Ikeda, T., Takatsuka, Y., Toi, M., Suwa, T., & Ohashi, Y. (2002) · Annals of Oncology · doi:10.1093/annonc/mdg014 · Cited by 38
Vergote, I. B., Bonneterre, J. M., Thurlimann, B. J. K., et al. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00239-2 · Cited by 34
Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer
Bonnefoi, H. R., Smith, I. E., Dowsett, M., Trunet, P., Houston, S., da Luz, R., Rubens, R., Coombes, R. C., & Powles, T. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.93 · Cited by 32
Kaufmann, M., Bajetta, E., Dirix, L., Fein, L. E., Jones, S. E., Červek, J., Fowst, C., Polli, A., di Salle, E., Massimini, G., et al. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00240-9 · Cited by 29
Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer
Bajetta, E., Zilembo, N., Buzzoni, R., et al. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.265 · Cited by 24
Russell, C. A., Green, S., O’Sullivan, J. M., Hynes, H. E., Budd, G. T., Congdon, J. E., Martino, S., & Osborne, C. K. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2494 · Cited by 23
ARIMIDEX: a Potent and Selective Aromatase Inhibitor for the Treatment of Advanced Breast Cancer
Buzdar, A. U., Jonat, W., Howell, A., & Plourde, P. V. (1997) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(97)80006-4 · Cited by 22
Advanced breast cancer updates on anastrozole versus tamoxifen
Nabholtz, J. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00374-1 · Cited by 21
Kleeberg, U. R., Dowsett, M., Carrion, R. P., Dodwell, D. J., Vorobiof, D., Aparicio, L. A., & Robertson, J. F. R. (2009) · Oncology · doi:10.1159/000227752 · Cited by 21
Bernhard, J., Castiglione‐Gertsch, M., Schmitz, S. ‐. H., Thurlimann, B. J. K., Cavalli, F., Morant, R., Fey, M. F., Bonnefoi, H. R., Goldhirsch, A., & Hürny, C. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00028-3 · Cited by 21
Vorobiof, D., Kleeberg, U. R., Pérez-Carrión, R., Dodwell, D. J., Robertson, J. F. R., Calvo, L., Dowsett, M., & Clack, G. (1999) · Annals of Oncology · doi:10.1023/a:1008308609325 · Cited by 20
Rose, C., Kamby, C., Mouridsen, H. T., Andersson, M., Bastholt, L., Møller, K. A., ANDERSEN, J. E., Munkholm, P. S., Dombernowsky, P., & Christensen, I. J. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006460925986 · Cited by 18
Falkson, G., Raats, J., & Falkson, H. (1992) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(92)90202-t · Cited by 18
Bruning, P. F., Bonfrer, J. M. G., Hart, A. A. M., van der Linden, E., Jong‐Bakker, M. D., Moolenaar, A. J., & Nooijen, W. J. (1989) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(89)90032-1 · Cited by 17
Beretta, K., Hoeffken, K., Kvinnsland, S., et al. (1990) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a057795 · Cited by 16
Svenstrup, B., Herrstedt, J., Brünner, N., et al. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90168-6 · Cited by 15
Fadrozole versus Megestrol Acetate: A Double-Blind Randomised Trial in Advanced Breast Cancer
Bezwoda, W. R., Gudgeon, A., Falkson, G., Jordaan, J. P., & Goedhals, L. (1998) · Oncology · doi:10.1159/000011888 · Cited by 15
Mercer, P. M., Ebbs, S. R., Fraser, S. C. A., Coltart, R. S., & Bates, T. (1993) · PubMed · Cited by 12
Drummond, M., Thompson, E., Howell, A., Jonat, W., Buzdar, A. U., & Brown, J. S. (1999) · Journal of Medical Economics · doi:10.3111/199902033043 · Cited by 11
Second-Line Hormonotherapy for Breast Cancer
Pronzato, P., RUBAGOTTI, A., AMOROSO, D., Bertelli, G., Queirolo, P., Sertoli, M. R., Rosso, M., Gallotti, P., Monzeglio, C., & Rosso, R. (1993) · American Journal of Clinical Oncology · doi:10.1097/00000421-199312000-00013 · Cited by 9
Tobias, J. S., & Howell, A. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.02.030 · Cited by 8
Vergote, I. B. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00287-3 · Cited by 6
Cited by
Rugo, H. S., Rumble, R. B., Macrae, E., Barton, D. L., Connolly, H. K., Dickler, M. N., Fallowfield, L., Fowble, B., Ingle, J. N., Jahanzeb, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1487 · Cited by 633
Cardoso, F., Fallowfield, L., Costa, A., Castiglione, M., & Senkus, E. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr372 · Cited by 596
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu385 · Cited by 540
NCCN Guidelines Insights: Breast Cancer, Version 1.2017
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0044 · Cited by 529
Cardoso, F., Harbeck, N., Fallowfield, L., Kyriakides, S., & Senkus, E. (2012) · Annals of Oncology · doi:10.1093/annonc/mds232 · Cited by 485
Metadata
- Authors
- Gibson, L., Lawrence, D., Dawson, C., & Bliss, J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2009-10-07
- Volume
- 2021
- Issue
- 2
- Pages
- CD003370-CD003370
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1946355969
- Cited by
- 252
- References
- 82
- FWCI
- 7.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.